| Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors M Ameratunga, M Chénard-Poirier, IM Candilejo, M Pedregal, A Lui, ... European journal of cancer 89, 56-63, 2018 | 67 | 2018 |
| A review of mTOR pathway inhibitors in gynecologic cancer AC de Melo, E Paulino, ÁHI Garces Oxidative Medicine and Cellular Longevity 2017 (1), 4809751, 2017 | 63 | 2017 |
| Targeting ATR in cancer medicine R Sundar, J Brown, AI Russo, TA Yap Current problems in cancer 41 (4), 302-315, 2017 | 58 | 2017 |
| Coronary heart disease risk assessment in HIV‐infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions MM Moreira Guimaraes, D Bartolomeu Greco, AH Ingles Garces, ... International journal of clinical practice 64 (6), 739-745, 2010 | 48 | 2010 |
| Treatment of ovarian cancer beyond chemotherapy: are we hitting the target? ÁHI Garces, MSF Dias, E Paulino, CGM Ferreira, AC de Melo Cancer chemotherapy and pharmacology 75, 221-234, 2015 | 44 | 2015 |
| Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer AH Ingles Garces, L Au, R Mason, J Thomas, J Larkin Expert Opinion on Investigational Drugs 28 (8), 695-708, 2019 | 39 | 2019 |
| Current and emerging systemic therapies for cutaneous metastatic melanoma R Mason, L Au, A Ingles Garces, J Larkin Expert Opinion on Pharmacotherapy 20 (9), 1135-1152, 2019 | 39 | 2019 |
| Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer B Basu, MG Krebs, R Sundar, RH Wilson, J Spicer, R Jones, M Brada, ... Annals of Oncology 29 (9), 1918-1925, 2018 | 33 | 2018 |
| A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I AC de Melo, R Grazziotin-Reisner, F Erlich, MS Fontes Dias, G Moralez, ... Cancer chemotherapy and pharmacology 78, 101-109, 2016 | 27 | 2016 |
| Patterns of care and outcome of elderly women diagnosed with cervical cancer in the developing world A Nogueira-Rodrigues, AC de Melo, AHI Garces, E Paulino, FVG Alves, ... International Journal of Gynecologic Cancer 26 (7), 2016 | 24 | 2016 |
| First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: a retrospective analysis of patients treated at Brazilian National Cancer Institute ÁHI Garces, PAR Mora, FVG Alves, CC do Carmo, R Grazziotin, ... International Journal of Gynecologic Cancer 23 (4), 2013 | 22 | 2013 |
| A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials AHI Garces, JE Ang, M Ameratunga, M Chénard-Poirier, D Dolling, ... European Journal of Cancer 104, 32-38, 2018 | 20 | 2018 |
| An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors. U Banerji, AH Ingles Garces, V Michalarea, R Ruddle, FI Raynaud, ... Journal of clinical oncology 35 (15_suppl), 2503-2503, 2017 | 16 | 2017 |
| Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review V Michalarea, E Fontana, AI Garces, A Williams, EC Smyth, S Picchia, ... Current Problems in Cancer 43 (5), 487-494, 2019 | 13 | 2019 |
| Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the … E Moreira, E Paulino, ÁH Ingles Garces, MS Fontes Dias, M Saramago, ... Medical Oncology 35, 1-5, 2018 | 11 | 2018 |
| Breast cancer-associated venous thromboembolism: a case–control study D Rebouças, M Costa, L Thuler, A Garces, L Aquino, J Bines The Breast 28, 84-88, 2016 | 9 | 2016 |
| Carboplatina e paclitaxel em primeira linha paliativa no tratamento de câncer de colo uterino avançado ou persistente/recorrente: análise de uma série de casos do Instituto … ÁHI Garces, PAR Mora, FVG Alves Revista Brasileira de Oncologia Clínica Vol 9 (31), 2013 | 7 | 2013 |
| Clinical trial designs for evaluating and exploiting cancer evolution AHI Garces, N Porta, TA Graham, U Banerji Cancer Treatment Reviews, 102583, 2023 | 5 | 2023 |
| A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade … S Banerjee, V Michalarea, JE Ang, A Ingles Garces, A Biondo, ... Clinical Cancer Research 28 (21), 4634-4641, 2022 | 5 | 2022 |
| Exploiting HPV-induced carcinogenesis for a rational drug development in cervical Cancer A Nogueira-Rodrigues, AC Melo, G Werutsky, AHI Garces, CG Ferreira Current Cancer Drug Targets 16 (3), 249-260, 2016 | 5 | 2016 |
